Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.55 |
| ▸ | TCF7 | P36402 | 2/20 | 0.55 |
| ▸ | BCL9 | O00512 | 1/20 | 0.55 |
| ▸ | TCF4 | P15884 | 1/20 | 0.55 |
| ▸ | CLPP | Q16740 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745871 | 0.94 | CTNNB1 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL749342 | 0.94 | CTNNB1 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL751936 | 0.94 | CTNNB1 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL751476 | 0.93 | CYP3A4 (0.60) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL12020491 | 0.92 | CYP3A4 (0.53) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL748776 | 0.91 | CTNNB1 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL747959 | 0.91 | CTNNB1 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL748970 | 0.91 | CTNNB1 (0.55) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL750541 | 0.90 | CTNNB1 (0.59) | CYP3A4CTNNB1TCF7BCL9TCF4 | |
| SCHEMBL747342 | 0.90 | CLPP (0.51) | CYP3A4CTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2015-02-26 | — | — | US | disclosed |
| US-8729262-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2014-05-20 | — | — | US | disclosed |
| US-8318738-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-11-27 | — | — | US | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8138337-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-03-20 | — | — | US | disclosed |
| US-8106049-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-8101751-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2012-01-24 | — | — | US | disclosed |
| US-20110294797-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | CHOONGWAE PHARMA CORPORATION (KR) | 2011-12-01 | — | — | US | disclosed |
| US-8049008-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2011-11-01 | — | — | US | disclosed |
| US-7585862-B2 | Colorectal cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis disease, tuberous sclerosis complex, Alzheimer's disease, excess hair growth or loss | CHOONGWAE PHARMA CORPORATION (KR) | 2009-09-08 | — | — | US | disclosed |
| US-7576084-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-08-18 | — | — | US | disclosed |
| US-7566711-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2009-07-28 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-02-22 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021431-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057283-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CYP3A4 4757/4885CTNNB1 14/4885TCF7 49/4885 |
| US-20070043052-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CYP3A4 4757/4885CTNNB1 14/4885TCF7 49/4885 |
| US-20070021431-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CYP3A4 4757/4885CTNNB1 14/4885TCF7 49/4885 |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CYP3A4 4757/4885CTNNB1 14/4885TCF7 49/4885 |
| US-20110294797-A1 | REVERSE-TURN MIMETICS AND METHOD RELATING THERETO | WNT1, APC, WNT3 | CYP3A4 4757/4885CTNNB1 14/4885TCF7 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.